Drug Profile
JCAR 023
Alternative Names: Anti-CD171-CAR-T-cell-therapy-Juno-Therapeutics; Anti-CD171-chimeric-antigen-receptor-T-cell-therapy-Juno-Therapeutics; Anti-CD171-human-scFv-CAR-T-cell-product-Juno-Therapeutics; Anti-CD171-human-scFv-CAR-T-cell-therapy-Juno-Therapeutics; Anti-CD171-human-single-chain-variable-fragment-CAR-T-cell-therapy-Juno Therapeutics; Anti-L1CAM-CAR-T-cell-therapy-Juno-Therapeutics; Anti-neural-cell-adhesion-molecule-L1-chimeric-antigen-receptor-T-cell-therapy-Juno Therapeutics; Anti-neural-cell-adhesion-molecule-L1-human-scFv-CAR-T-cell-product-Juno Therapeutics; Anti-neural-cell-adhesion-molecule-L1-human-scFv-CAR-T-cell-therapy-Juno Therapeutics; Anti-neural-cell-adhesion-molecule-L1-human-single-chain-variable-fragment-CAR-T-cell-therapy-Juno Therapeutics; JCAR023Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Seattle Childrens Research Institute
- Developer Juno Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuroblastoma
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Neuroblastoma(In adolescents, In children, In infants, Recurrent, Refractory metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 13 May 2020 JCAR 023 is still in phase I trials for Neuroblastoma in USA (NCT02311621)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Neuroblastoma(In adolescents, In children, In infants, Recurrent, Refractory metastatic disease) in USA (Parenteral)